ZBIO (Zenas BioPharma) ROC %: -873.55% (As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $25.79
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma ROC %?

Zenas BioPharma ZBIO +4.86% 12 ROC % is -873.55% as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zenas BioPharma's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -873.55%.

As of today (2026-06-28), Zenas BioPharma's WACC % is 10.44%. Zenas BioPharma's ROC % is -854.18% (calculated using TTM income statement data). Zenas BioPharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zenas BioPharma  (NAS:ZBIO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zenas BioPharma's WACC % is 10.44%. Zenas BioPharma's ROC % is -854.18% (calculated using TTM income statement data). Zenas BioPharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zenas BioPharma ROC % Related Terms


Zenas BioPharma ROC % Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma ROC % Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC %
-672.56 -215.15 -881.31 -605.55

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -684.10 -1,061.52 -678.82 -700.73 -873.55
ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma ROC % Calculation

Zenas BioPharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-211.385 * ( 1 - 0.02% )/( (23.138 + 46.664)/ 2 )
=-211.342723/34.901
=-605.55 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=369.968 - 48.199 - ( 350.766 - max(0, 57.292 - 355.923+350.766))
=23.138

Zenas BioPharma's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-309.4 * ( 1 - 0% )/( (46.664 + 24.173)/ 2 )
=-309.4/35.4185
=-873.55 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=747.682 - 54.506 - ( 717.205 - max(0, 61.161 - 730.164+717.205))
=24.173

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -873.55% mean?
Zenas BioPharma (ZBIO) has a ROC % of -873.55% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's ROC % too high?
Zenas BioPharma's current ROC % is -873.55%. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's ROC % compare to MNKD and OLMA?
Zenas BioPharma's ROC % of -873.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current ROC % is -873.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current ROC % of -873.55%. The current ROC % is -873.55%. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current ROC % is -873.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.79
Price